CENTESSA PHARMACEUTICALS PLC ADS news, videos and press releases - Page 2
For more news please use our advanced search feature.
CENTESSA PHARMACEUTICALS PLC ADS - More news...
CENTESSA PHARMACEUTICALS PLC ADS - More news...
- Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
- Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for SerpinPC for Hemophilia B
- Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023
- Centessa Pharmaceuticals Reports Recent Business Progress and Financial Results for the Fourth Quarter and Full-Year 2022
- Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
- Centessa Pharmaceuticals Announces Addition of Patrick Yue, MD, as Senior Vice President of Clinical Development, Innovative Medicines
- Centessa Pharmaceuticals to Present Additional Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
- Centessa Pharmaceuticals Announces Presentation at the SVB Securities Global Biopharma Conference
- Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors
- Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia
- Centessa Pharmaceuticals Announces New Chief People Officer Karen Anderson
- Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2022
- Centessa Pharmaceuticals to Present Additional 18-Months of Continued Treatment Data with SerpinPC from Open-Label Extension of Phase 2a Study at 64th ASH Annual Meeting
- Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
- Centessa Pharmaceuticals Announces Poster Presentation Featuring Novel Orexin Receptor 2 (OX2R) Agonist Discovery Pipeline at the 26th Conference of the European Sleep Research Society (Sleep Europe 2022)
- Centessa Pharmaceuticals Announces Orphan Drug Designation Granted to SerpinPC for the Treatment of Hemophilia B
- Centessa Pharmaceuticals Announces Non-Human Primate Pharmacokinetic and Safety Data for LB101 (PD-L1xCD47) Demonstrating Potential for Enhanced Therapeutic Index
- Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
- INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses of $100,000 to Contact the Firm
- ONGOING INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses of $100,000 to Contact the Firm
- INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses of $100,000 to Contact the Firm
- Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2022; Provides Program Update for ZF874
- Centessa Pharmaceuticals Announces Addition of Harris L. Rotman, PhD, as Senior Vice President of Regulatory Affairs
- Centessa Pharmaceuticals Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors
- Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
- Centessa Pharmaceuticals Announces Poster Presentation of First Preclinical Data for LockBody® Program at 2022 ASCO Annual Meeting
- Centessa Pharmaceuticals Makes Strategic Decision to Discontinue Clinical Development of Lixivaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Centessa Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Updates
- Centessa Pharmaceuticals Reports Fourth Quarter and 2021 Financial Results and Provides Business Update
- Centessa Pharmaceuticals to Present at the Guggenheim Genomic Medicines & Rare Disease Day
